CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

Charles Peterfy; Yan Chen; Peter Countryman; Bartosz Chmielowski; Stephen P. Anthony; John H. Healey; Zev A. Wainberg; Allen L. Cohn; Geoffrey I. Shapiro; Vicki L. Keedy; Arun Singh; Igor Puzanov; Andrew J. Wagner; Meng Qian; Mike Sterba; Henry H. Hsu; Sandra Tong-Starksen; William D. Tap

doi:10.2217/fon-2021-1437

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

Charles Peterfy
, Yan Chen
, Peter Countryman
, Bartosz Chmielowski
, Stephen P. Anthony
, John H. Healey
, Zev A. Wainberg
, Allen L. Cohn
, Geoffrey I. Shapiro
, Vicki L. Keedy
, Arun Singh
, Igor Puzanov
, Andrew J. Wagner
, Meng Qian
, Mike Sterba
, Henry H. Hsu
, Sandra Tong-Starksen
, William D. Tap

Medicine

Spire Sciences
University of California at Los Angeles
Evergreen Hematology and Oncology
Cornell University
Rocky Mountain Cancer Centers
Harvard University
Vanderbilt University
Daiichi Sankyo Company, Limited
Plexxikon, Inc.

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Aim: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those by tumor volume score (TVS) and modified RECIST (m-RECIST). Materials & methods: MRIs acquired every two cycles were assessed centrally using RECIST 1.1, m-RECIST and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94% of patients (29/31) showed a decrease in tumor size (median change: -60% [RECIST], -66% [m-RECIST], -79% [TVS]). All methods showed 100% disease control rate. For TDS, improvements were seen in bone erosion (32%), bone marrow edema (58%) and knee effusion (46%). Conclusion: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT.

Original language	English
Pages (from-to)	1449-1459
Number of pages	11
Journal	Future Oncology
Volume	18
Issue number	12
DOIs	https://doi.org/10.2217/fon-2021-1437
State	Published - Apr 2022

Keywords

MRI
RECIST
modified RECIST
pexidartinib
tenosynovial giant cell tumor
tissue damage score
tumor volume score

Access to Document

10.2217/fon-2021-1437

Cite this

Peterfy, C., Chen, Y., Countryman, P., Chmielowski, B., Anthony, S. P., Healey, J. H., Wainberg, Z. A., Cohn, A. L., Shapiro, G. I., Keedy, V. L., Singh, A., Puzanov, I., Wagner, A. J., Qian, M., Sterba, M., Hsu, H. H., Tong-Starksen, S., & Tap, W. D. (2022). CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden. Future Oncology, 18(12), 1449-1459. https://doi.org/10.2217/fon-2021-1437

@article{e23092d4bff2492b8e3c962ad3a38fa5,

title = "CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden",

abstract = "Aim: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those by tumor volume score (TVS) and modified RECIST (m-RECIST). Materials \& methods: MRIs acquired every two cycles were assessed centrally using RECIST 1.1, m-RECIST and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94\% of patients (29/31) showed a decrease in tumor size (median change: -60\% [RECIST], -66\% [m-RECIST], -79\% [TVS]). All methods showed 100\% disease control rate. For TDS, improvements were seen in bone erosion (32\%), bone marrow edema (58\%) and knee effusion (46\%). Conclusion: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT.",

keywords = "MRI, RECIST, modified RECIST, pexidartinib, tenosynovial giant cell tumor, tissue damage score, tumor volume score",

author = "Charles Peterfy and Yan Chen and Peter Countryman and Bartosz Chmielowski and Anthony, \{Stephen P.\} and Healey, \{John H.\} and Wainberg, \{Zev A.\} and Cohn, \{Allen L.\} and Shapiro, \{Geoffrey I.\} and Keedy, \{Vicki L.\} and Arun Singh and Igor Puzanov and Wagner, \{Andrew J.\} and Meng Qian and Mike Sterba and Hsu, \{Henry H.\} and Sandra Tong-Starksen and Tap, \{William D.\}",

note = "Publisher Copyright: {\textcopyright} 2022 Charles Peterfy.",

year = "2022",

month = apr,

doi = "10.2217/fon-2021-1437",

language = "English",

volume = "18",

pages = "1449--1459",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

Peterfy, C, Chen, Y, Countryman, P, Chmielowski, B, Anthony, SP, Healey, JH, Wainberg, ZA, Cohn, AL, Shapiro, GI, Keedy, VL, Singh, A, Puzanov, I, Wagner, AJ, Qian, M, Sterba, M, Hsu, HH, Tong-Starksen, S & Tap, WD 2022, 'CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden', Future Oncology, vol. 18, no. 12, pp. 1449-1459. https://doi.org/10.2217/fon-2021-1437

TY - JOUR

T1 - CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

AU - Peterfy, Charles

AU - Chen, Yan

AU - Countryman, Peter

AU - Chmielowski, Bartosz

AU - Anthony, Stephen P.

AU - Healey, John H.

AU - Wainberg, Zev A.

AU - Cohn, Allen L.

AU - Shapiro, Geoffrey I.

AU - Keedy, Vicki L.

AU - Singh, Arun

AU - Puzanov, Igor

AU - Wagner, Andrew J.

AU - Qian, Meng

AU - Sterba, Mike

AU - Hsu, Henry H.

AU - Tong-Starksen, Sandra

AU - Tap, William D.

PY - 2022/4

Y1 - 2022/4

N2 - Aim: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those by tumor volume score (TVS) and modified RECIST (m-RECIST). Materials & methods: MRIs acquired every two cycles were assessed centrally using RECIST 1.1, m-RECIST and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94% of patients (29/31) showed a decrease in tumor size (median change: -60% [RECIST], -66% [m-RECIST], -79% [TVS]). All methods showed 100% disease control rate. For TDS, improvements were seen in bone erosion (32%), bone marrow edema (58%) and knee effusion (46%). Conclusion: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT.

AB - Aim: Monitoring treatment of tenosynovial giant cell tumor (TGCT) is complicated by the irregular shape and asymmetrical growth of the tumor. We compared responses to pexidartinib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with those by tumor volume score (TVS) and modified RECIST (m-RECIST). Materials & methods: MRIs acquired every two cycles were assessed centrally using RECIST 1.1, m-RECIST and TVS and tissue damage score (TDS). Results: Thirty-one evaluable TGCT patients were treated with pexidartinib. From baseline to last visit, 94% of patients (29/31) showed a decrease in tumor size (median change: -60% [RECIST], -66% [m-RECIST], -79% [TVS]). All methods showed 100% disease control rate. For TDS, improvements were seen in bone erosion (32%), bone marrow edema (58%) and knee effusion (46%). Conclusion: TVS and m-RECIST offer potentially superior alternatives to conventional RECIST for monitoring disease progression and treatment response in TGCT. TDS adds important information about joint damage associated with TGCT.

KW - MRI

KW - RECIST

KW - modified RECIST

KW - pexidartinib

KW - tenosynovial giant cell tumor

KW - tissue damage score

KW - tumor volume score

UR - https://www.scopus.com/pages/publications/85128161051

U2 - 10.2217/fon-2021-1437

DO - 10.2217/fon-2021-1437

M3 - Article

C2 - 35040698

AN - SCOPUS:85128161051

SN - 1479-6694

VL - 18

SP - 1449

EP - 1459

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this